title: FDA approval of paroxetine for menopausal hot flushes.
authors.affiliation: From the Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD.
authors.forename: Ronald J
authors.initials: RJ
authors.lastname: Orleans
authors.forename: Li
authors.initials: L
authors.lastname: Li
authors.forename: Myong-Jin
authors.initials: MJ
authors.lastname: Kim
authors.forename: Jia
authors.initials: J
authors.lastname: Guo
authors.forename: Mahboob
authors.initials: M
authors.lastname: Sobhan
authors.forename: Lisa
authors.initials: L
authors.lastname: Soule
authors.forename: Hylton V
authors.initials: HV
authors.lastname: Joffe
mesh_terms: D026683:Advisory Committees; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D019389:Cytochrome P-450 CYP2D6 / Q000187:drug effects; D017277:Drug Approval; D004347:Drug Interactions; D005260:Female; D019584:Hot Flashes / Q000188:drug therapy*; D006801:Humans; D017374:Paroxetine / Q000494:pharmacology / Q000627:therapeutic use*; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D059020:Suicidal Ideation; D013629:Tamoxifen / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D018931:Antineoplastic Agents, Hormonal; D019389:Cytochrome P-450 CYP2D6; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors; D013629:Tamoxifen